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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.03.001BACKGROUND AND OBJECTIVES: There is limited information regarding the outcome of patients treated for
leukemia during pregnancy. This study was performed on all cases of leukemia during pregnancy identified in
our institution leukemia database.
PATIENTS AND METHODS: It is a retrospective study from our existing database. Thirty two cases were identified
among the cohort of patients treated for acute and chronic leukemia between January 1991 and July 2003.
RESULTS: Among the acute leukemia patients (n = 21), 10 patients (47.6%) received chemotherapy during preg-
nancy, seven had live birth and three had spontaneous abortion. No teratogenicity or congenital malformations or
postnatal complication were reported. The remaining 11 (52.4%) were not given chemotherapy while pregnant;
three patients presented after 34 weeks of gestation ending in normal live births and then received chemotherapy
and eight patients had abortion before starting chemotherapy. Among the chronic myeloid leukemia (CML) patients
(n = 11), nine patients received hydroxyurea, one patient received alfa-interferon and one patient was treated with
leukapheresis. Eight patients had normal live births and three patients had abortion. Out of the 32 patients, 18
patients (56.2%) subsequently underwent HLA matched sibling allogeneic stem cell transplantation, seven for
acute myeloid leukemia (AML), two for acute lymphocytic leukemia (ALL) and nine for CML. After a median follow
up of 16 years, five patients (15.6%) are alive in remission (one from chemotherapy group and four from SCT group).
CONCLUSIONS: Our report lends credence to the safety and feasibility of administering anti-leukemic therapy in
acute and chronic leukemias during pregnancy although acute leukemia patients had possibly a poor long term out-
come compared to non-pregnant patients.
KEYWORDS: Pregnancy; Acute leukemia; Chronic leukemia; ChemotherapyThe coincident occurrence of pregnancy andleukemia presents complex therapeuticdilemmas for the patient, the hematologist,
and the obstetrician. Experience in the management
of pregnant mothers with leukemia is limited. Despite
advances in the treatment of leukemia, which have
prolonged survival and even made cure possible in
many instances, the low incidence of leukemia occur-
ring during pregnancy and possibly the under report-
ing of cases have adversely affected the understanding
of managing such cases.Cancer develops in about one per 1000 pregnant
women with an estimated annual incidence of leuke-
mia in 1 per 100,000 pregnancies.1,2 Approximately
500 cases of leukemia during pregnancy have been
reported so far in the literature. Reporting such cases
has helped physicians in making decisions on treat-
ment options, and has shown that delay in treatment
of pregnant women with acute leukemia is detrimen-
tal.3 However, many issues are yet to be clariﬁed
regarding the management of the leukemic mother
and the developing fetus.63
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To add to the understanding of management
issues and outcomes of leukemia during pregnancy,
we present our experience in the largest case series
of patients from a single institution.PATIENTS AND METHODS
This review of cases was initiated as part of a broad
report of all cancer cases during pregnancy at the
Department of Oncology at King Faisal Specialist
Hospital and Research Center, Riyadh, Saudi Arabia.
After approval by the Research Ethics Committee
(institutional review board), the institutional leukemia
database was searched for all cases of leukemia and
pregnancy seen from January 1991 to July 2003.
There were 505 cases of adult leukemia: 131 cases
of acute lymphoblastic leukemia (ALL), 180 acute
myeloid leukemia (AML), 193 chronic myelogenous
leukemia (CML), and one case of chronic lymphocytic
leukemia (CLL). Of the 505 cases, we identiﬁed 32
who presented with pregnancy at the time of diagno-
sis and treatment.
The medical records of all identiﬁed cases were
reviewed. Extracted data included demographic data,
type of leukemia, gestational age at diagnosis, and
results of investigations, including bone marrow, ﬂow
cytometry and cytogenetics, management during preg-
nancy, and fetal and maternal outcomes.RESULTS
We identiﬁed 32 cases of leukemia during pregnancy
among the cohort of patients treated between January
1991 and July 2003. At diagnosis, the median age was
24.5 years (range 17–40 years) and the median gesta-
tional age was 16 weeks (range 4–40 weeks). Ten
patients were primigravida and the rest were multipa-
rous. Twenty-one cases were acute leukemia and 11
cases were CML. Cytogenetic analysis was available
for 27(84%) cases.
Results and relevant data are summarized under
the headings of acute and chronic leukemias below:
Acute leukemia
Twenty-one cases (15 cases of AML and six cases of
ALL) were diagnosed with almost equal incidence in
all trimesters. Six cases (four myeloid and two lym-
phoid) of 21 had spontaneous abortions and two
opted to have therapeutic abortions at eight weeks
of gestation (Table 1). Three patients (two AML,
one ALL) presented late in their pregnancies at 34,
38 and 40 weeks of gestation, respectively. They were
offered induction chemotherapy after delivery (two ofHemathem by cesarean section and one vaginal delivery). All
three achieved complete remission (CR) (Table 1).
The remaining ten patients (seven myeloid and
three lymphoid) received chemotherapy during the
second and third trimesters.
Of the seven myeloid patients who received che-
motherapy, three were diagnosed with acute promye-
locytic leukemia (APL), and four were non-APL.
Two APL patients were induced with single agent
all-trans-retinoic acid (ATRA) and the third patient
received ATRA with ‘3 + 7’ chemotherapy (Dauno-
rubicin 45 mg/m2/day IV on days 1, 2, 3 and cytosine
arabinoside 100 mg/m2/day continuous IV infusion
from day 1–7) due to poor response with ATRA.
The non-APL group requiring chemotherapy were
induced with conventional ‘3 + 7’ chemotherapy.
Three out of four achieved remission after the ﬁrst
induction cycle and one required salvage chemother-
apy due to the presence of blasts on day14 bone mar-
row examination. Among these seven patients treated
with chemotherapeutic agents, four had full term
delivery and one had premature delivery at 32 weeks
(Table 1).
Among six ALL patients, ﬁve were B-ALL and one
was T-cell ALL. Three of them received chemother-
apy; two patients received conventional ﬁve-drug reg-
imen comprising vincristine, adriamycin, prednisone,
cyclophosphamide and L-asparaginase, and one
received vincristine plus prednisone only. One had full
term delivery, one had premature delivery, and one
had spontaneous abortion (shown in Table 1). All
of them achieved CR.
Chronic Leukemia
All patients with chronic leukemia were diagnosed as
Philadelphia positive CML. The mean presenting
WBC count was 134.9 · 109/L (range 24.9–
307 · 109/L), mean hemoglobin concentration was
105.8 g/L (range 84–126 g/L) and mean platelet
count was 449 · 109/L (range 147–101 · 109/L).
One patient was treated with alfa-interferon, one with
leukapheresis, and the remaining patients were treated
with hydroxyurea (HU). In the HU treated group,
two aborted spontaneously; one at 11 weeks, and
the other one at 17 weeks of gestation. All others
had normal live births; ﬁve of them at full term, one
at 37 weeks and one at 30 weeks of gestation
(Table 1).
Stem cell transplantation (SCT)
Among the 32 patients, 18 patients underwent alloge-
neic stem cell transplantation (SCT) from their HLA
matched sibling donors; seven AML, two ALL, andtol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.com
Table 1. Patient characteristics and outcomes.
No. Year of diagnosis Diagnosis with cytogenetics Patient age/gravida Gestational age Treatment Pregnancy outcome Patient outcome
1 23-Jan-1991 CML 46XX, t(9;22) 40/8 4 HU Spontaneous abortion at 11 weeks Lost follow up
2 05-Jun-1991 CML 46XX, t(9;22) 18/2 8 HU Spontaneous abortion at 11 weeks Died post SCT due to TRM
3 20-Nov-1991 AML M5 Not done 25/3 13 Doxorubicin, cytarabine Live birth at 38 weeks Died post SCT due to TRM
4 07-Feb-1992 CML 46XX, t(9;22) 29/3 11 HU Live birth at 41 weeks Died post SCT due to TRM
5 16-Apr-1992 Pre B-ALL Normal 23/2 38 None Live birth at 38 weeks Died of PD
6 08-Feb-1994 CML 46XX, t(9;22) 22/1 25 Leukapheresis Live birth at 34 weeks Lost follow up
7 13-Mar-1994 CML 46XX, t(9;22) 39/7 17 HU Live birth at 40 weeks Died post SCT due to TRM
8 13-Apr-1994 AML M2 Normal 33/4 40 None Live birth at 40 weeks Alive in CR
9 15-Jul-1994 AML M4 Not done 35/1 8 None Therapeutic abortion Died post SCT due to TRM
10 21-Jul-1994 AML M3 46xx, t(15;17) 21/1 8 None Therapeutic abortion Died of PD
11 15-Jul-1995 AML M3 46xx, t(15;17) 22/1 37 ATRA Live birth at 40 weeks Died post SCT due to TRM
12 15-Aug-1995 AML M3 46xx, t(15;17) 30/8 15 ATRA Spontaneous abortion at 19 weeks Lost follow up
13 24-Sept-1995 CML 46XX, t(9;22) 28/7 30 Interferon Live birth at 39 weeks Died post SCT due to TRM
14 01-Dec-1995 AML M3 46xx, t(15;17) 25/5 20 None Spontaneous abortion at 20 weeks Lost follow up
15 29-Apr-1996 AML M2 46xx, t(8;21), t(20;22) 22/4 16 Daunorubicin, cytarabine Live birth at 39 weeks Died post SCT due to PD
16 05-Jun-1996 AML/MDS 46xx, del7p 39/3 16 None Spontaneous abortion at 19 weeks Died of PD
17 14-Jun-1997 AML M3 46xx, t(15;17), t(8;18) 17/2 18 ATRA Daunorubicin, cytarabine Spontaneous abortion at 19 weeks Lost follow up
18 18-Jun-1997 Pre B ALL 47xx,+x, t(4;11)(q21,p23) 25/1 12 None Spontaneous abortion at 13 weeks Died of PD
19 22-Jul-1997 AML/MDS 7q,t(9;22), 11q23 24/1 14 None Spontaneous abortion at 16 weeks Lost follow up
20 05-Oct-1997 CML 46XX, t(9;22) 23/1 6 HU Live birth at 39 weeks Post SCT in CR
21 19-Jul-1998 AML M2 46xx, t(3;17)t(8;21) 24/3 34 None Live birth at 39 weeks Died post SCT due to TRM
22 01-Dec-1998 AML M4 48xx, inv16,+8,+21 24/2 23 Doxorubicin, cytarabine Spontaneous abortion at 16 weeks Died post SCT due to PD
23 17-Feb-1999 CML 46XX, t(9;22) 28/8 26 HU Live birth at 40 weeks Alive in CR post SCT
24 09-Feb-2000 AML M5 Not done 40/11 12 None Spontaneous abortion Died of PD
25 17-Feb-2000 Pre B ALL Not done 26/3 28 5-drug regimen Spontaneous abortion Alive in CR post SCT
26 09-Aug-2000 Pre B ALL Not done 23/3 13 None Spontaneous abortion at 14 weeks Died post SCT due to PD
27 16-May-2001 Pre B ALL 46xx, t(4;11)(q21,q23) 37/7 29 5-drug regimen Live birth at 38 weeks Lost follow up
(Continued on next page)
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nine CML. After a median follow up of 16 years, four
patients out of 18 (22.2%) are alive while survival for
the non-pregnant transplant group from the same
cohort is 48% (data not yet published). Among the
deaths, nine patients died due to transplant-related
mortality (TRM), and ﬁve patients died due to pro-
gressive disease (PD).DISCUSSION
Since the diagnosis of the ﬁrst case of leukemia in
pregnancy by Virchow in 1845,3 the management of
cases remains under debate. Controversies arise
regarding time of treatment initiation, and safest reg-
imens to use for both mother and fetus. Management
is complicated by heightened emotions that include
religious and ethical issues. We treated 32 cases of
pregnancy with leukemia at different gestational peri-
ods, with both acute and chronic cases.
There were more leukemia cases diagnosed in the
second and third trimesters, which is relatively similar
to other reported case series.4 The same is true for
acute leukemia cases in comparison to chronic leuke-
mia cases (21 versus 11 cases). The incidence of spon-
taneous abortion was approximately 28%, which
correlates with other studies, though the exact etiol-
ogy remains unexplained.4–6
Acute leukemia
We managed 21 cases of acute leukemia during the
study period. The myeloid type was more common
than the lymphoid (5:2), which correlates with non-
pregnant counterparts. The incidence of acute leuke-
mia was equal in all trimesters. Most of the literature
shows fewer number of cases in the ﬁrst trimester,4,7
while some studies reported fewer cases in the last tri-
mester.8,5 These variations do not support any corre-
lation of leukemia incidence with gestational age.
It is now well-recognized that chemotherapy in the
ﬁrst trimester is highly teratogenic.9–13 We observed
a greater number of spontaneous abortions prior to
chemotherapy in the ﬁrst trimester. The risks and
beneﬁts were discussed with those who did not have
spontaneous abortion at the time of diagnosis, with
both the mother and her family before initiating che-
motherapy. The remaining patients chose to proceed
with therapeutic abortion. Pregnant patients were
not offered chemotherapy during the ﬁrst trimester.
No unexpected events were documented during spon-
taneous or therapeutic abortions, and all subsequently
received full doses of conventional chemotherapy. Our
experience suggests that therapeutic abortions can be
a safe option in the ﬁrst trimester of pregnancy, andtol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.com
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leukemia patients are able to receive standard induc-
tion chemotherapy afterwards.
Ten patients received chemotherapy during their
second and third trimesters. Among patients with
AML, other than APL, four were induced with stan-
dard ‘3 + 7’ chemotherapy comprising Daunorubicin
and cytosine arabinoside. Three of them achieved
remission after the ﬁrst cycle and the fourth one
required salvage to achieve remission. In the APL
group (three patients), two received single agent
ATRA and one received ATRA with ‘3 + 7’ chemo-
therapy. Among the seven cases of AML who received
active treatment, four had full term delivery, and one
had premature delivery at 32 weeks. ATRA is known
to have severe teratogenic effects during the ﬁrst tri-
mester of pregnancy, but there are reports showing
its safety during second and third trimester.14–16 Pac-
iﬁci et al.17 indicated that the placental transfer of
drugs administered to the mother is greatly dimin-
ished by its high molecular weight, particularly anth-
racyclines, which have a molecular weight greater than
500 Dalton, and an incomplete placental transfer.
Stewart et al.18 reported that the concentration of
anthracyclines in fetuses after intravenous injections
was 100 to 1000-fold below those found in adult tis-
sues. Among the three patients with ALL, two
patients received conventional ﬁve-drug regimen che-
motherapy, and one received treatment with vincris-
tine and prednisolone only, as the patient was in
late gestational stage. All patients were on usual ante-
natal follow-up in conjunction with hematology care.
Chemotherapy was well-tolerated with no unusual
chemo-toxicities requiring dose reduction or delay in
treatment administration. There was no report of
intra-uterine death or fetal malformation. Breast feed-
ing was discouraged and therefore none of the new-
borns were breast fed.
There was higher incidence of premature delivery,
which may explain the reason behind the low birth
weight. Germann et al.19 evaluated embryo-fetal out-
come in 160 cases that were exposed to anthracyclines
during pregnancy. Their recommendation is to use
anthracyclines in a standard dose, preferably as bolus
or short infusion from second trimester until two
weeks before delivery. Aviles et al.20 published prom-
ising data that described 84 children who were exposed
to chemotherapy in utero, had long term follow-up
(median 18.7 years) with no congenital, neurological
or psychological adverse effects, and with no observed
effect on learning and educational capacity.Hematol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.coChronic leukemia
All CML patients in this study were treated before
the tyrosine-kinase inhibitor era. Among the 10
CML cases, one patient was treated with alfa-inter-
feron, one with leukapheresis and the other eight were
treated with hydroxyurea (HU). From the HU trea-
ted group, two were aborted spontaneously at
11 weeks of gestation and one abortion occurred prior
to start of treatment. All others had normal live
births; ﬁve at full term, one at 37 weeks and one at
thirty weeks. HU was well tolerated and there was
no evidence of any fetal malformations. Although ani-
mal models show HU in high concentration is associ-
ated with embryo toxicity by producing signiﬁcant
amount of free radicals and reducing the uterine blood
ﬂow, published literature does not show evidence of
fetal malformation with HU in human.21,22 Our
experience also suggests that HU is a potential option
for managing patients with CML during pregnancy.
Leukapheresis is also a safe option for CML
patients with very high white cell count prior to start-
ing other therapy. Interferon-alfa is considered one of
the safest therapies for CML during pregnancy due to
its lack of inhibition of DNA synthesis, and because it
has a large molecular weight of around 19KD, which
limits its ability to cross the placental barrier. Its
minor presence in placentas, amniotic ﬂuid and
fetal membranes is considered safe to fetal
development.CONCLUSION
A high CR rate can be achieved in leukemia during
pregnancy. Chemotherapy did not lead to any terato-
genic effects among live births. All spontaneous and
therapeutic abortions were more likely to be disease-
related complications than chemotherapy-induced.
Delay and suboptimal induction therapy in these cases
puts them into a relatively higher risk category, con-
tributing to lower long term survival, irrespective of
leukemia type.
This case series, which is the largest from a single
institution, clearly supports early treatment of leuke-
mia during pregnancy based on the underlying disease
rather than concomitant pregnancy. Treatment
appears to be safe and may lead to a better outcome.CONFLICT OF INTEREST
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